Tay-Sachs Disease Pipeline Insight Market Research 2019 report by Mart Research outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tay-Sachs Disease pipeline landscape is provided which includes the disease overview and Tay-Sachs Disease treatment guidelines. The assessment part of the report embraces, in depth Tay-Sachs Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tay-Sachs Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Tay-Sachs Disease Understanding

According to National Organization for Rare Disorders (NORD), Tay-Sachs disease is a rare, neurodegenerative disorder in which deficiency of an enzyme hexosaminidase A results in excessive accumulation of certain fats (lipids) known as gangliosides in the brain and nerve cells. This abnormal accumulation of gangliosides leads to progressive dysfunction of the central nervous system. This disorder is categorized as a lysosomal storage disease. Tay-Sachs disease is broken down into the classic or infantile form, the juvenile form, and the adult or late-onset form. In individuals with infantile Tay-Sachs disease, symptoms typically first appear between three and five months of age. In individuals with the late-onset form, symptoms may become apparent anytime from adolescence through the mid-30s.

Browse Full Tay-Sachs Disease Pipeline Insight Market Research Report @ https://martresearch.com/market-analysis/tay-sachs-disease-pipeline-insight/2/42159

Companies Covered in Tay-Sachs Disease Pipeline Insight Mart ResearchAxovant Gene TherapiesIntraBioActelion PharmaceuticalsCastle Creek PharmaceuticalsAvigenGene Therapy Research InstitutionOxford Glycobiology InstituteAmicus TherapeuticsAldagenRecursion Pharmaceuticals

Drugs Covered in Tay-Sachs Disease Pipeline Insight Market Research Report:AXO AAV GM2N-Acetyl-L-LeucineMiglustatCCP 010Lysosomal storage disease gene therapyResearch programme: Tay-Sachs disease gene therapyAcetylleucineResearch programme: calcium channel modulatorsCDP 923Research programme: Lysosomal storage disorder therapeuticsALD 601Research programme: rare genetic disorder therapeutics

r is categorized as a lysosomal storage disease. Tay-Sachs disease is broken down into the classic or infantile form, the juvenile form, and the adult or late-onset form. In individuals with infantile Tay-Sachs disease, symptoms typically first appear between three and five months of age. In individuals with the late-onset form, symptoms may become apparent anytime from adolescence through the mid-30s.

Companies Covered in Tay-Sachs Disease Pipeline Insight Market Research Report:

Axovant Gene Therapies

IntraBio

Actelion Pharmaceuticals

Castle Creek Pharmaceuticals

Avigen

Gene Therapy Research Institution

Oxford Glycobiology Institute

Amicus Therapeutics

Aldagen

Recursion Pharmaceuticals

Drugs Covered in Tay-Sachs Disease Pipeline Insight Market Research Report:

AXO AAV GM2

N-Acetyl-L-Leucine

Miglustat

CCP 010

Lysosomal storage disease gene therapy

Research programme: Tay-Sachs disease gene therapy

Acetylleucine

Research programme: calcium channel modulators

CDP 923

Research programme: Lysosomal storage disorder therapeutics

ALD 601

Research programme: rare genetic disorder therapeutics

Tay Sachs disease Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Tay Sachs disease targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Tay Sachs disease pipeline report covers 6+ companies. Some of the key players include IntraBio Inc (IB1001-201), Castle Creek Pharmaceuticals (CCP 010) etc.

The report is built using data and information traced from the researchers proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Tay Sachs disease Analytical Perspective by Mart Research

In-depth Tay-Sachs Disease Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Tay-Sachs Disease Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

To Buy Tay-Sachs Disease Pipeline Insight Market Research Report @ https://martresearch.com/paymentform/2/42159/Single_User

Scope of the report

The Tay Sachs disease report provides an overview of therapeutic pipeline activity for Tay Sachs disease across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Tay Sachs disease therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Tay Sachs disease Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Tay Sachs disease

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Tay Sachs disease to formulate effective R&D strategies

Assess challenges and opportunities that influence Tay Sachs disease R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage. Get in detail information of each product with updated information on each project along with key milestones. Devise Tay Sachs disease in licensing and out licensing strategies by identifying prospective partners with progressing projects for Tay Sachs disease to enhance and expand business potential and scope. Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs.

Table of Content for Tay-Sachs Disease Pipeline Insight Market Research Report:Chapter One: Report IntroductionChapter Two: Tay-Sachs Disease (GM2 gangliosidosis, type 1, HexA deficiency, Hexosaminidase A deficiency, Hexosaminidase alpha-subunit deficiency (variant B))Chapter Three: Tay-Sachs Disease Current Treatment PatternsChapter Four: Tay-Sachs Disease Mart Researchs Analytical PerspectiveChapter Five: Tay-Sachs Disease Pipeline TherapeuticsChapter Six: Tay-Sachs Disease -Products AnalysisChapter Seven: Recent TechnologiesChapter Eight: Tay-Sachs Disease Key CompaniesChapter Nine: Tay-Sachs Disease Key ProductsChapter Ten: Dormant and Discontinued ProductsChapter Eleven: Tay-Sachs Disease Unmet NeedsChapter Twelve: Tay-Sachs Disease Future Perspectives

List of Tables for Tay-Sachs Disease Pipeline Insight Market Research Report:Table 1. Diagnostic GuidelinesTable 2. Treatment GuidelinesTable 3. Assessment SummaryTable 4. Company-Company Collaborations (Licensing / Partnering) AnalysisTable 5. Tay-Sachs Disease Acquisition AnalysisTable 6. Assessment by Phase of DevelopmentTable 7. Assessment by Product Type (Mono / Combination)Table 8. Assessment by Stage and Product TypeTable 9. Assessment by Route of AdministrationTable 10. Assessment by Stage and Route of AdministrationTable 11. Assessment by Molecule TypeTable 12. Assessment by Stage and Molecule TypeTable 13. Assessment by MOATable 14. Assessment by Stage and MOATable 15. Late Stage Products (Phase-III)Table 16. Mid Stage Products (Phase-II)Table 17. Early Stage Products (Phase-I)Table 18. Pre-clinical and Discovery Stage ProductsTable 19. Inactive ProductsTable 20. Dormant ProductsTable 21. Discontinued Products

To Check Discount on Tay-Sachs Disease Pipeline Insight Market Research Report @ https://martresearch.com/contact/discount/2/42159

About us: Research is and will always be the key to success and growth for any industry. Most organizations invest a major chunk of their resources viz. time, money and manpower in research to achieve new breakthroughs in their businesses. The outcome might not always be as expected thereby arising the need for precise, factual and high-quality data backing your research. This is where MART RESEARCH steps in and caters its expertise in the domain of market research reports to industries across varied sectors.

Contact Us:

Mart Researchsales@martresearch.com+1-857-300-1122

Read more:
Tay-Sachs Disease Pipeline Insight Market Research Report 2019: by Trends, Development, Types, Therapeutics, Drugs, Clinical Trials, Competitive...

Comments are closed.